Can apixaban prevent venous thromboembolism better than rivaroxaban? - Authors' reply

Antiemetic Combination Use During the First Trimester and Adverse Circulatory Outcomes in Newborn Infants: A Data-Mining Analysis.

Drug safety·2026

HIV Pre-Exposure Prophylaxis Care Continuum in Outpatient Settings: A Systematic Review and Meta-Analysis.

AJPM focus·2026

Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026

Inpatient and Postacute Care After Head and Neck Surgery Among Beneficiaries.

Laryngoscope investigative otolaryngology·2026

Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026

Early Calcium Replacement Is Associated With Reduced Mortality in Transfusion After Injury.

The Journal of surgical research·2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

The Lancet. Haematology·2026

Beyond maximum grade: key regulatory considerations in adverse event reporting.

The Lancet. Haematology·2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

The Lancet. Haematology·2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

The Lancet. Haematology·2026

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The Lancet. Haematology·2026

A cost-effective conventional endpoint PCR assay for HLA-B*13:01 genotyping to guide personalized dapsone therapy in leprosy in low-resource settings.

Personalized medicine·2026

Variation in Attribute Prioritization and Design of Discrete Choice Experiments Across Pharmaceuticals and Medical Devices Patient Preference: A Systematic Review.

Patient preference and adherence·2026

Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.

Cureus·2026

A transcriptomics-based computational drug repurposing pipeline identifies simvastatin and primaquine as therapeutics for endometriosis.

iScience·2026

Evaluating seltorexant as a treatment option for major depressive disorder.

Expert review of neurotherapeutics·2026

Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.

International journal of obesity (2005)·2026

Related Experiment Videos

Can apixaban prevent venous thromboembolism better than rivaroxaban? - Authors' reply

Related Concept Videos

Antiemetic Combination Use During the First Trimester and Adverse Circulatory Outcomes in Newborn Infants: A Data-Mining Analysis.

HIV Pre-Exposure Prophylaxis Care Continuum in Outpatient Settings: A Systematic Review and Meta-Analysis.

Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis.

Inpatient and Postacute Care After Head and Neck Surgery Among Beneficiaries.

Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study.

Early Calcium Replacement Is Associated With Reduced Mortality in Transfusion After Injury.

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Beyond maximum grade: key regulatory considerations in adverse event reporting.

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

A cost-effective conventional endpoint PCR assay for HLA-B*13:01 genotyping to guide personalized dapsone therapy in leprosy in low-resource settings.

Variation in Attribute Prioritization and Design of Discrete Choice Experiments Across Pharmaceuticals and Medical Devices Patient Preference: A Systematic Review.

Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.

A transcriptomics-based computational drug repurposing pipeline identifies simvastatin and primaquine as therapeutics for endometriosis.

Evaluating seltorexant as a treatment option for major depressive disorder.

Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.

Related Experiment Videos

Can apixaban prevent venous thromboembolism better than rivaroxaban? - Authors' reply

Related Concept Videos

Related Articles